characteristics
News
10.12.2019
Asclepion Laser Technologies: Steady growth enables investment in the future
On September 9, an extension to the main building of Asclepion Laser Technologies GmbH was inaugurated and the usable floor space almost doubled by a further 2,500 m2 during a […]
14.03.2016
Merck Initiates Phase III Study of MSB11022
Merck, a leading science and technology company, today announced the initiation of a global Phase III clinical study of MSB11022, a proposed biosimilar of adalimumab, in chronic plaque psoriasis. This […]
21.01.2021
Asclepion Laser Technologies: Innovative partner for your aesthetic practice
To develop innovative and successful products is the ethos of Asclepion Laser Technologies. Therefore, the company invests intensively in research and medical practice. The goal is to make the advantages […]